Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development

Information generated from economic evaluation is increasingly being used to inform health resource allocation decisions globally, including in low- and middle- income countries. However, a crucial consideration for users of the information at a policy level, e.g. funding agencies, is whether the studies are comparable, provide sufficient detail to inform policy decision making, and incorporate inputs from data sources that are reliable and relevant to the context. This review was conducted to inform a methodological standardisation workstream at the Bill and Melinda Gates Foundation (BMGF) and assesses BMGF-funded cost-per-DALY economic evaluations in four programme areas (malaria, tuberculosis, HIV/AIDS and vaccines) in terms of variation in methodology, use of evidence, and quality of reporting. The findings suggest that there is room for improvement in the three areas of assessment, and support the case for the introduction of a standardised methodology or reference case by the BMGF. The findings are also instructive for all institutions that fund economic evaluations in LMICs and who have a desire to improve the ability of economic evaluations to inform resource allocation decisions.

[1]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[2]  T. Jefferson,et al.  Quality of economic evaluations in health care , 2002, BMJ : British Medical Journal.

[3]  Mohsen Naghavi,et al.  GBD 2010: design, definitions, and metrics , 2012, The Lancet.

[4]  S. Goldie,et al.  Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. , 2008, Vaccine.

[5]  S. Al-Aqeel State of health economic evaluation research in Saudi Arabia: a review , 2012, ClinicoEconomics and outcomes research : CEOR.

[6]  Bjarne Robberstad,et al.  Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review , 2012, BMC Medical Informatics and Decision Making.

[7]  M. Tanner,et al.  The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub-Saharan Africa , 2010, PloS one.

[8]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, Clinical therapeutics.

[9]  D. Constenla Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. , 2008, Revista panamericana de salud publica = Pan American journal of public health.

[10]  A. Mbonye,et al.  Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[11]  K. Floyd,et al.  Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the Philippines , 2006, PLoS medicine.

[12]  E. Marseille,et al.  Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study , 2011, Cost effectiveness and resource allocation : C/E.

[13]  C. Menéndez,et al.  Cost-Effectiveness of Intermittent Preventive Treatment of Malaria in Pregnancy in Southern Mozambique , 2010, PloS one.

[14]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[15]  B. Sharp,et al.  Malaria Journal BioMed Central Research Costs and consequences of large-scale vector control for malaria , 2022 .

[16]  Mark Sculpher,et al.  Common Methodological Flaws in Economic Evaluations , 2005, Medical care.

[17]  S. Goldie,et al.  Health and economic impact of rotavirus vaccination in GAVI-eligible countries , 2010, BMC public health.

[18]  Dan Greenberg,et al.  Bias in published cost effectiveness studies: systematic review , 2006, BMJ : British Medical Journal.

[19]  Franziska Wulf,et al.  Methods For The Economic Evaluation Of Health Care Programmes , 2016 .

[20]  V. Wiseman,et al.  Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign , 2008, Malaria Journal.

[21]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  S. Goldie,et al.  Economic evaluation of pneumococcal conjugate vaccination in The Gambia , 2010, BMC infectious diseases.

[23]  M. E. Hoque,et al.  A systematic review of economic evaluations of health and health-related interventions in Bangladesh , 2011, Cost Effectiveness and Resource Allocation.

[24]  Y. Tozan,et al.  Prereferral rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness analysis , 2010, The Lancet.

[25]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[26]  S. Aljunid,et al.  Health-care systems and pharmacoeconomic research in Asia-Pacific region. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Thomas A. Smith,et al.  Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. , 2006, The American journal of tropical medicine and hygiene.

[28]  J. Menu,et al.  WHO in Cambodia , 1995 .

[29]  Eddy R. Segura,et al.  The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study , 2012, PLoS medicine.

[30]  J. Fox-Rushby,et al.  Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. , 2000, Health economics.

[31]  S. Ozawa,et al.  Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. , 2012, Vaccine.

[32]  M. Buxton,et al.  Economic Evaluation and Decision Making in the UK , 2012, PharmacoEconomics.

[33]  S. Touch,et al.  A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. , 2010, Vaccine.

[34]  J. Ross,et al.  The use of economic evaluation in health care: Australian decision makers' perceptions. , 1995, Health policy.

[35]  M. Tanner,et al.  Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. , 2009, Bulletin of the World Health Organization.

[36]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[37]  C. Poulos,et al.  Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  Y. Teerawattananon,et al.  Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  J. Salomon,et al.  Cost-effectiveness of Rotavirus vaccination in Vietnam , 2009, BMC public health.

[40]  P. Kilgore,et al.  Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. , 2003, Bulletin of the World Health Organization.

[41]  Keith Abrams,et al.  Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997 , 2005, Journal of health services research & policy.

[42]  Fabrizio Tediosi,et al.  Simulation of the cost-effectiveness of malaria vaccines , 2009, Malaria Journal.